CJC-1295 Perimenopause Support Protocol

Why GH Declines in Perimenopause and Why It Matters

Growth hormone output falls roughly 14% per decade after age 30, and estrogen actively sustains GH pulse amplitude through hypothalamic GHRH neurons. When estradiol drops during perimenopause, the already-aging somatotropic axis loses a second layer of support at the same time.

A controlled clinical study published in the Journal of Clinical Endocrinology and Metabolism confirmed that 24-hour GH secretion is substantially lower in postmenopausal women compared with premenopausal controls, and that physiological estradiol replacement partially restores pulsatile GH output (Veldhuis et al., JCEM 1997). The implication for perimenopause is that GH-axis support and hormonal support are not competing strategies; they may be complementary.

The Consequence for Body Composition

Lean mass and visceral fat are both sensitive to GH. Adults with confirmed GH deficiency carry an average of 7 kg more fat mass than age-matched controls, concentrated in the abdominal depot, according to a meta-analysis in JCEM (Maison et al., JCEM 2004). Perimenopausal women face this same shift without a formal GH-deficiency diagnosis, because their decline is age-physiological rather than pathological.

The Sleep Connection

Stage III and stage IV slow-wave sleep (SWS) is when most nightly GH pulses fire. Sleep architecture deteriorates during perimenopause through both hot-flash-driven arousals and a primary reduction in SWS that tracks falling GH. Stimulating endogenous GH release with a GHRH analogue may help restore the GH-SWS feedback loop rather than interrupting it, as exogenous recombinant GH would.

What CJC-1295 Is and How It Differs from Sermorelin

CJC-1295 is a synthetic 29-amino-acid GHRH analogue with a drug-affinity complex (DAC) modification that extends its half-life to approximately 6 to 8 days after a single subcutaneous dose. Sermorelin, the older GHRH analogue, has a half-life under 10 minutes.

DAC vs. Non-DAC Formulations

Clinicians sometimes specify "CJC-1295 without DAC," which is chemically identical to modified GRF(1-29) and behaves more like sermorelin, with a half-life of 20 to 30 minutes. The DAC version produces a sustained elevation of GH and IGF-1 over days rather than a single pulsatile spike. For perimenopause applications that target sleep-phase GH release, many practitioners prefer the non-DAC form dosed nightly because it better mimics physiological pulsatility. Both formulations exist in clinical use, and the protocol below covers both.

A pharmacokinetic study of CJC-1295 with DAC showed that a single 2 mg/kg intravenous dose produced GH elevations sustained over 6 days and IGF-1 increases of 2- to 3-fold lasting up to 14 days (Jetté et al., JCEM 2005). Subcutaneous dosing at lower clinical doses produces a more modest, titrable response.

Why Not Just Use Recombinant GH?

FDA-approved recombinant human GH (somatropin) is indicated for confirmed adult GH deficiency with two or more pituitary hormone deficiencies plus a GH stimulation test below diagnostic threshold. Using recombinant GH off-label in perimenopausal women suppresses endogenous GH secretion through negative feedback and carries a higher side-effect burden (edema, carpal tunnel syndrome, insulin resistance). A GHRH analogue works upstream, preserving the pituitary's own feedback circuitry and reducing the ceiling on IGF-1 overshoot.

The Clinical Protocol: Dosing, Timing, and Cycle Structure

Starting Dose and Titration

The starting subcutaneous dose most used in off-label clinical practice is 100 mcg of CJC-1295 (with or without DAC) injected 30 to 60 minutes before sleep. The stomach should be empty for at least 90 minutes before injection because elevated insulin blunts the GH response to GHRH stimulation.

Titration schedule for the standard 16-week cycle:

• Weeks 1 to 4: 100 mcg, 5 nights per week. Assess sleep quality and morning energy subjectively.
• Weeks 5 to 8: Increase to 200 mcg if IGF-1 at week 4 remains below 200 ng/mL and no side effects have appeared. Check IGF-1 at week 8.
• Weeks 9 to 16: Hold at 200 mcg or advance to 300 mcg maximum if IGF-1 is still below the age-adjusted upper limit (typically 250 to 290 ng/mL for women aged 40 to 55).

Women who report strong sleep improvement and measurable body composition changes at 200 mcg rarely need 300 mcg.

Pairing with Ipamorelin: The Case for a GHRP Stack

Many perimenopause protocols pair CJC-1295 with ipamorelin, a selective growth hormone secretagogue that acts on the ghrelin receptor (GHSR-1a). Ipamorelin adds a separate, synergistic GH pulse mechanism without meaningfully raising cortisol or prolactin, a side-effect profile that separates it from older GHRPs like GHRP-2 and GHRP-6.

A dose of 100 to 200 mcg of ipamorelin given in the same subcutaneous injection as CJC-1295 at bedtime is the most common combination. The clinical rationale: CJC-1295 opens the GHRH receptor window; ipamorelin simultaneously opens the ghrelin receptor, producing a synergistic GH pulse amplitude that more closely resembles the GH release seen in younger women.

Injection Technique

Use a 28- to 31-gauge, 0.5-inch insulin syringe. Reconstitute lyophilized peptide with bacteriostatic water (2 mL per 5 mg vial is a common reconstitution). Store reconstituted peptide refrigerated at 2 to 8°C, protected from light. Rotate injection sites across the abdomen, lateral thigh, or anterior thigh to minimize lipodystrophy. Discard reconstituted vials after 30 days.

Monitoring Labs and Safety Parameters

Off-label peptide use demands proactive lab monitoring. The following schedule is the minimum standard recommended for perimenopause patients on CJC-1295.

Baseline Labs (Before First Injection)

• IGF-1 (serum, fasting preferred)
• Fasting glucose and insulin
• HbA1c
• Estradiol and FSH (to stage perimenopause)
• Thyroid panel (TSH, free T4): hypothyroidism blunts GH response
• Cortisol (8 a.m.)
• Prolactin
• Comprehensive metabolic panel

On-Cycle Labs (Week 8)

• IGF-1: target the mid-to-upper range for age. The Endocrine Society's clinical practice guideline on adult GH deficiency establishes age-normalized IGF-1 reference ranges and recommends maintaining IGF-1 within the normal range for age during any GH-axis therapy (Molitch et al., JCEM 2011).
• Fasting glucose: GH is counter-regulatory to insulin. A rise of more than 10 mg/dL from baseline warrants dose reduction or cycle cessation in women with pre-diabetes risk.
• HbA1c if baseline was borderline (<5.7% is ideal before starting)

Post-Cycle Labs (Week 16 or at Cycle End)

Full repeat of baseline panel. A DEXA scan at baseline and week 16 provides objective body composition data (lean mass, fat mass, visceral fat area) and is the gold standard for tracking peptide-driven recomposition.

The HealthRX Perimenopause GH-Axis Decision Framework: Before initiating CJC-1295, screen for three contraindications that supersede any potential benefit. Active malignancy, confirmed acromegaly or GH excess (IGF-1 above the age-adjusted upper limit at baseline), and uncontrolled type 2 diabetes (HbA1c >8%) each represent absolute stop conditions. Women with a personal history of hormone-sensitive cancers should discuss this protocol with their oncologist before proceeding.

Expected Timeline of Outcomes

Weeks 2 to 4: Sleep and Recovery

The earliest and most consistent reported change is subjective improvement in sleep depth. This aligns with the mechanism: increased GH pulsatility during SWS. Women commonly report fewer nighttime awakenings and more restorative sleep by week 3. One reason this occurs early is that GH itself has sleep-promoting effects mediated through somatostatin withdrawal; the Endocrine Society notes that GH secretion and SWS are tightly coupled in younger adults (Van Cauter et al., JCEM 2000).

Weeks 4 to 8: Energy, Skin, and Cognition

Mid-cycle, women often note improved daytime energy, faster post-exercise recovery, and subtle skin texture changes consistent with increased dermal collagen synthesis. Collagen production is a downstream effect of IGF-1, which stimulates fibroblast proliferation. A randomized controlled trial on GH replacement in GH-deficient adults demonstrated significant improvement in quality-of-life scores including energy and mood within 6 to 8 weeks (Götherström et al., JCEM 2007).

These early changes are real. They are not placebo-proof, but they correspond to measurable IGF-1 rises.

Weeks 8 to 16: Body Composition

Lean mass gains and visceral fat reduction require the full cycle. Adults on GH-axis therapy in RCT settings typically show 1 to 2 kg of lean mass increase and 1 to 2 kg of fat mass reduction over 12 to 24 weeks, depending on baseline GH deficiency severity. An RCT of GHRH therapy in healthy older adults published in JAMA (N=89) demonstrated that 6 months of GHRH administration increased IGF-1 by 55% and improved body composition (lean mass up, fat mass down) compared with placebo (Corpas et al., JAMA 1992). Women who also engage in progressive resistance training during the cycle show amplified lean mass responses.

Integrating CJC-1295 with HRT: The Co-Treatment Logic

Most perimenopausal women presenting for peptide therapy are also candidates for menopausal hormone therapy (MHT). The 2023 Menopause Society position statement supports MHT initiation in symptomatic women under age 60 or within 10 years of menopause onset, citing cardiovascular and bone benefits alongside symptom relief (The Menopause Society, 2023).

How Estrogen and GH-Axis Therapies Interact

Oral estrogen raises sex-hormone-binding globulin (SHBG) and reduces IGF-1 bioavailability by increasing hepatic clearance. Transdermal estradiol avoids first-pass hepatic effects and does not suppress IGF-1 to the same degree. For women on CJC-1295 who also use MHT, transdermal delivery is therefore preferred to preserve the IGF-1 signal generated by the peptide.

A secondary analysis of the Growth Hormone Research Society's consensus recommendations noted that women receiving oral estrogen require higher GH doses to achieve equivalent IGF-1 targets compared with women on transdermal estrogen (Ho et al., JCEM 2007).

Progesterone Considerations

Micronized progesterone (e.g., Prometrium 100 to 200 mg oral at bedtime) independently improves SWS in perimenopausal women, according to a randomized crossover trial (N=29) that found 300 mg oral micronized progesterone significantly increased SWS time vs. Placebo (Caufriez et al., Am J Physiol 2011). Stacking nightly micronized progesterone with a bedtime CJC-1295 injection may produce additive SWS benefits; both act on different steps of the same outcome pathway.

Side Effects and Risk Management

Common, Manageable Side Effects

• Injection-site reactions: Mild erythema, transient itching. Rotate sites.
• Water retention: Mild peripheral edema from GH-driven sodium retention occurs in roughly 10 to 15% of users in the first two weeks. Dose reduction to 100 mcg usually resolves it within 5 to 7 days.
• Headache: Most common in the first week. Usually self-limiting. Reducing dose or spacing injections to every-other-night during week 1 is effective.
• Morning joint stiffness: GH-related arthralgia is dose-dependent. Dropping from 300 to 200 mcg reliably reduces severity.

Side Effects Requiring Cycle Cessation

• Fasting glucose rising by more than 15 mg/dL above baseline (sustained over two measurements)
• IGF-1 exceeding the age-adjusted upper reference limit at any lab draw
• New or worsening carpal tunnel symptoms unresponsive to dose reduction

Populations Who Should Not Use This Protocol

Women with a history of pituitary tumors, active malignancy, or uncontrolled diabetes (HbA1c >8%) should not use CJC-1295 in any formulation. The FDA has not approved CJC-1295 for any indication, and compounded peptide products are regulated under 503A or 503B pharmacy frameworks (FDA, 2024). Women should obtain compounded peptides only through licensed 503A pharmacies with a valid clinician prescription.

Nutrition and Lifestyle Variables That Amplify the Protocol

Protein Intake

IGF-1 is nutritionally sensitive. Low protein intake blunts the IGF-1 response to GHRH stimulation. A controlled study demonstrated that protein restriction reduced IGF-1 by 30 to 40% independent of caloric status (Thissen et al., Endocr Rev 1994). Women on this protocol should target 1.6 to 2.0 g of protein per kg of body weight per day.

Fasting Before Injection

Somatostatin (GH's primary inhibitor) is suppressed by low insulin. Injecting CJC-1295 at least 90 minutes after the last meal, when insulin is at its nadir, allows the peptide to drive the largest possible GH pulse. Post-meal insulin elevation can reduce GH pulse amplitude by 50% or more.

Resistance Training Timing

GH and IGF-1 are anabolic amplifiers, not standalone muscle-builders. Women who incorporate 3 to 4 sessions per week of resistance training see 2 to 3x greater lean mass response in GH-axis studies than sedentary controls. Schedule resistance sessions on injection evenings when possible; the training-induced GH pulse and the peptide-induced pulse may be additive within the same 24-hour window.

Regulatory and Prescribing Context

CJC-1295 is not FDA-approved for any therapeutic use in the United States. The peptide exists in a compounding pharmacy framework. As of 2024, the FDA removed several GH secretagogue peptides from 503A compounding eligibility lists citing concerns about demonstrated clinical utility and safety data. Clinicians prescribing CJC-1295 should verify current 503A eligibility with their compounding pharmacy at time of prescribing.

Patients should receive a written informed consent document detailing the off-label, investigational nature of this therapy, the absence of long-term safety data in perimenopausal women specifically, and the requirement for ongoing lab monitoring. The Growth Hormone Research Society's 2019 consensus statement specifies that GH-axis therapy outside approved indications requires documentation of clinical rationale and regular safety reviews (Bidlingmaier et al., JCEM 2019).